Cargando…

Evaluation of ceftriaxone-sulbactam-disodium edetate adjuvant combination against multi-drug resistant Gram-negative organisms

BACKGROUND: Multi-drug resistant (MDR) Gram-negative bacteria are an emerging threat, both in hospital and community settings. As very few antibiotics are effective against such infections, the need of the hour is a new antibiotic or drug combination which can overcome the effect of extended-spectru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Shilpi, Kumar, Mahadevan, Shergill, Shelinder P.S., Tandel, Kundan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AOSIS 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736688/ https://www.ncbi.nlm.nih.gov/pubmed/33354525 http://dx.doi.org/10.4102/ajlm.v9i1.991

Ejemplares similares

Safety and efficacy of a novel drug elores (ceftriaxone + sulbactam + disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study
por: Chaudhary, Manu, et al.
Publicado: (2017)

Simple spectrophotometric method for estimation of disodium edetate in topical gel formulations
por: Kamboj, Sunil, et al.
Publicado: (2011)

Urinary Metal Levels after Repeated Edetate Disodium Infusions: Preliminary Findings
por: Alam, Zenith H., et al.
Publicado: (2020)

Edetate Disodium-based Treatment in a Woman with Diabetes and Critical Limb Ischemia Scheduled for Lower Extremity Amputation
por: Ujueta, Francisco, et al.
Publicado: (2019)

Limb Preservation Using Edetate Disodium-based Chelation in Patients with Diabetes and Critical Limb Ischemia: An Open-label Pilot Study
por: Arenas, Ivan, et al.
Publicado: (2019)

Ceftriaxone+Sulbactam+Disodium EDTA Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial
por: Mir, Mohd Amin, et al.
Publicado: (2019)

A Comparative In Vitro Sensitivity Study of “Ceftriaxone–Sulbactam–EDTA” and Various Antibiotics against Gram-negative Bacterial Isolates from Intensive Care Unit
por: Singh, Sweta, et al.
Publicado: (2020)

381. Effect of Ceftriaxone+sulbactam+disodium EDTA Combination in Treatment of Complicated Urinary Tract Infections Caused by Metallo Beta-lactamase Producing Enterobacterales: An Open Label Randomized Controlled Trial
por: Samantaray, Subhashree, et al.
Publicado: (2023)

A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections
por: Xin, Xiaojuan, et al.
Publicado: (2013)

An In Vitro Susceptibility Study of Cefotaxime-Sulbactam on Clinical Bacterial Isolates From Various Regions in India: A Comparison With Ceftriaxone-Sulbactam
por: Gondane, Ajitkumar A, et al.
Publicado: (2023)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
por: Wang, Xueting, et al.
Publicado: (2023)

Burden of extensively drug-resistant and pandrug-resistant Gram-negative bacteria at a tertiary-care centre
por: Bhatt, Puneet, et al.
Publicado: (2015)

A Novel High Performance Liquid Chromatographic Method for Simultaneous Determination of Ceftriaxone and Sulbactam in Sulbactomax
por: Shrivastava, Sanjay Mohan, et al.
Publicado: (2009)

In Vitro Susceptibility of Clinical Isolates to Ceftriaxone Alone and Ceftriaxone in Combination With Sulbactam or Tazobactam: A Comparative Study of Broad-Spectrum β-Lactam Antibiotics in India
por: Sanghavi, Sonali, et al.
Publicado: (2023)

Cefoperazone-Sulbactam Associated Refractory Seizures
por: Chovatiya, Harshad, et al.
Publicado: (2021)

200. Comparison of Clinical Outcomes among Patients Treated with Ceftriaxone 2 Grams versus 1 Gram Daily for Gram-Negative Bacteremia
por: Huynh-Phan, Ricky, et al.
Publicado: (2023)

In Vitro Activity of Various Sulbactam Compounds and Piperacillin/Tazobactam against Clinical Isolates of Different Gram-Negative Bacteria
por: Xiao, Shunian, et al.
Publicado: (2021)

Comparison between Ceftriaxone and Sulbactam-Ampicillin as Initial Treatment of Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis
por: Kato, Hideo, et al.
Publicado: (2022)

Retracted: In Vitro Activity of Various Sulbactam Compounds and Piperacillin/Tazobactam against Clinical Isolates of Different Gram-Negative Bacteria
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Protective role of ceftriaxone plus sulbactam with VRP1034 on oxidative stress, hematological and enzymatic parameters in cadmium toxicity induced rat model
por: Dwivedi, Vivek Kumar, et al.
Publicado: (2012)

1959. Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes in Patients Infected With Ceftriaxone Non-Susceptible, Extended-Spectrum β-Lactamase and Multi-Drug-resistant Pathogens at Baseline
por: Mir, Mohd Amin, et al.
Publicado: (2018)

Carbapenem vs. Piperacillin-tazobactam for the Treatment of Ceftriaxone-Resistant Gram-Negative Bacteremia: Matched Cohorts by Propensity Score
por: Rajagopal, Sumanth, et al.
Publicado: (2017)

Modest and variable efficacy of pre-exposure hydroxocobalamin and dicobalt edetate in a porcine model of acute cyanide salt poisoning
por: Thompson, Adrian, et al.
Publicado: (2019)

Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii
por: Temocin, Fatih, et al.
Publicado: (2015)

1373. Activity of Ceftriaxone–Sulbactam–EDTA Against Multi-Drug-resistant A. baumannii, P. aeruginosa and Enterobacteriaceae Isolates (WHO Critical Priority Pathogens) Collected from Various Hospitals in India
por: Girotra, Ruchi, et al.
Publicado: (2018)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
por: Palombo, Marta, et al.
Publicado: (2023)

Sensitization of Gram-Negative Bacteria to Aminoglycosides with 2-Aminoimidazole Adjuvants
por: Crotteau, Ashley N., et al.
Publicado: (2023)

Disodium 4,4′-oxydibenzoate
por: Yang, Yuan, et al.
Publicado: (2008)

Spectrum of fungal infections in COVID patients: The double whammy!
por: Lall, Mahima, et al.
Publicado: (2021)

Disodium tris(dioxidomolybdenum) bis(diarsenate)
por: Jouini, Raja, et al.
Publicado: (2012)

Hypersensitivity vasculitis induced by cefoperazone/sulbactam
por: Islek, Ismail, et al.
Publicado: (2003)

Cefoperazone/sulbactam-induced hemolytic anemia
por: Sun, XM, et al.
Publicado: (2023)

Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial
por: Hamao, Nobuyoshi, et al.
Publicado: (2020)

Clearance of Gram-Negative Bacterial Pathogens from the Ocular Surface by Predatory Bacteria
por: Romanowski, Eric G., et al.
Publicado: (2021)

The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam
por: de Oliveira, Maura S., et al.
Publicado: (2013)

Disodium (2RS,3SR)-tartrate
por: Arbuckle, William, et al.
Publicado: (2009)

1974. Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis
por: Mandale, Pankaj, et al.
Publicado: (2018)

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates
por: Pasteran, Fernando, et al.
Publicado: (2021)

Evaluation of different methods for in vitro susceptibility testing of colistin in carbapenem resistant Gram-negative bacilli
por: Rout, Bidyutprava, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jtcjhl441k8nmt80jejbh89drj